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ABSTRACT
Cancer is characterized by both genetic and epi-
genetic alterations. While cancer driver mutations
and copy-number alterations have been studied at
a systems-level, relatively little is known about the
systems-level patterns exhibited by their epigenetic
counterparts. Here we perform a pan-cancer wide
systems-level analysis, mapping candidate cancer-
driver DNA methylation (DNAm) alterations onto a
human interactome. We demonstrate that functional
DNAm alterations in cancer tend to map to nodes of
lower connectivity and inter-connectivity, compared
to the corresponding alterations at the genomic
level. We find that epigenetic alterations are relatively
over-represented in extracellular and transmem-
brane signaling domains, whereas cancer genes un-
dergoing amplification or deletion tend to be en-
riched within the intracellular domain. A pan-cancer
wide meta-analysis identifies WNT and chemokine
signaling, as two key pathways where epigenetic
deregulation preferentially targets extracellular com-
ponents. We further pinpoint specific chemokine
ligands/receptors whose epigenetic deregulation as-
sociates with key epigenetic enzymes, representing
potential targets for epigenetic therapy. Our results
suggest that epigenetic deregulation in cancer not
only targets tissue-specific transcription factors, but
also modulates signaling within the extra-cellular do-
main, providing novel system-level insight into the
potential distinctive role of genetic and epigenetic
alterations in cancer.
INTRODUCTION
Cancer is a complex disease that is caused by genetic and
epigenetic alterations (1). Somatic mutations, copy-number
and DNA methylation (DNAm) aberrations are all known
to influence transcript abundance in tumors, and thus may
define different types of ‘driver’ events (2–6). Many stud-
ies have mapped somatic mutations and copy-number aber-
rations onto signaling pathways and human protein inter-
actomes, revealing a number of ‘system-level’ insights (7–
14). For instance, such events map to central positions in
protein–protein interaction (PPI) networks (7,11,12) and
often exhibit patterns of mutual exclusivity within signal-
ing pathways (15,16).
In contrast to genomic alterations, it is only more re-
cently that studies have begun to explore how cancer-related
DNAm aberrations map onto signaling pathways and pro-
tein interactomes. For instance, some previous studies have
shown that cancer-associated DNAm changes tend to clus-
ter in such PPI networks, allowing interactome hotspots of
differential DNAm or of simultaneous differential DNAm
and mRNA expression, to be identified (6,17,18). In the
context of aging, it has been found that age-associated
DNAm drift occurs preferentially at genes of exception-
ally low connectivity that occupy peripheral network posi-
tions, in stark contrast to other age-related genes, includ-
ing longevity- and disease-associated genes (19). A similar
pattern was observed by Cheng (20) in the context of differ-
entially methylated genes associated with cancer survival.
However, no study has yet conducted an in-depth compar-
ison of the systems-level properties of epigenetic versus ge-
netic alterations in cancer.
The recent TCGA pan-cancer resource (21) now allows
for such an in-depth comparison. Specifically, we decided to
conduct a pan-cancer wide analysis at a systems-level, using
a highly curated PPI network, in order to address the fol-
lowing unexplored questions. First, do network topological
properties of functional DNAm aberrations in cancer differ
from those of functional somatic copy-number alterations
(SCNA) or those of cancer driver mutations? Second, do
epigenetic and genetic driver alterations target different do-
mains within the cell’s signaling hierarchy? Third, are there
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any particular signaling pathways that are more prone to
epigenetic versus genetic disruption, and if so, does this de-
pend on the signaling domain of the pathway?
Our pan-cancer analysis reveals that genetic and epige-
netic alterations not only target genes with different topo-
logical properties, but that these genes also exhibit a dif-
ferential pattern in terms of the cell’s signaling domain ar-
chitecture. These novel systems-level insights are consistent
with the view that a proportion of epigenetic cancer driver
events are mediated by extrinsic factors, i.e. the cellular en-
vironment.
MATERIALS AND METHODS
Datasets
Gene expression data. We downloaded the RNA-SeqV2
level 3 expression data fromTCGA (December 2014) for ten
cancer types, including breast invasive carcinoma (BRCA)
(22), bladder cancer (BLCA) (23), colon adenocarcinoma
(COAD) (24), head and neck squamous cell carcinoma
(HNSC) (25), kidney renal carcinoma (KIRC) (26), liver
hepatocellular carcinoma (LIHC) (27), lung adenocarci-
noma (LUAD) (28), lung squamous cell carcinoma (LUSC)
(29), thyroid carcinoma (THCA) (30) and uterine corpus
endometrial carcinoma (UCEC) (31) (The sample IDs are
provided in Supplementary Table S1). The level 3 RNA-Seq
data were processed further as follows: (i) zeroes were sub-
stituted by the minimum positive value of the dataset; (ii)
expression values were then log2 transformed in order to
regularize the data. (iii) Inter-array normalization was then
performed using the limma package (32).
DNAmethylation data. For the 10 cancer types mentioned
above, DNAm data generated with the Illumina Infinium
HumanMethylation450 BeadChip array were downloaded
from TCGA data portal. Probes with missing data (i.e.
NAs) in more than 30% of the samples were removed. The
rest of the probes with NAs were imputed using the k-
nearest neighbors (knn) (k=5) imputation procedure (33).
Subsequently, BMIQ was used to correct for the type II
probe bias (34).
Somatic copy number data. For the 10 cancer types men-
tioned above, we downloaded TCGA level-3 copy num-
ber segmentation data, which were generated from the
Affymetrix SNP 6.0 platform. We selected those files with
probes sorted according to the hg19 reference genome, and
with probes mapping to germline CNVs removed prior to
segmentation. When calling alterations, thresholds were set
based on the median of the log2 ratio for each array +2
or −2 computed using top 50% of the probes (ordered
by their log ratios) for calling gains and losses, respectively.
The median of the log2 ratio +4 or −4 was used to call
amplification and deletion respectively. In order to identify
the genes and features that were altered by copy number
aberrations, we searched for overlap of segments with gene
regions. The complete gene coordinates was given by hg19
using R package TxDb.Hsapiens.UCSC.hg19.knownGene.
A patient-by-gene call matrix was generated following a
similar procedure to (2) to capture different perspectives
of gene alterations, which has values representing discrete
copy number states. For each patient p and each gene g, we
identified segments s that overlap g and assign C(p, g) with
the copy number state of s. If gene g overlaps or is broken by
a set of segments, S= s1, . . . , sk, where k≥2, the copy num-
ber state of the segment with maximal severity(‘Neutral’
< ‘Gain/Loss’ < ‘Amplification/Deletion’) was assigned,
where ties were broken in samples exhibiting both a loss
and gain according to the maximal absolute value of the
segmented mean. The density distribution of non-zero en-
tries of copy number call matrices across 10 cancer types are
shown in Supplementary Figure S1.
Mutation data. For the ten cancer types mentioned above,
all mutation annotation format files were downloaded from
the TCGA.
Defining differentially methylated and differentially ex-
pressed genes
To assign DNAm values to a given gene, we assign to a gene
the average value of probes mapping to within 200 bp of
the transcription start site (TSS) of this gene. If no probes
map to within 200 bp of the TSS, we use the average of
probes mapping to the first exon of the gene. If such probes
are also not present, we use the average of probes mapping
towithin 1500 bp of the TSS. Justification for this procedure
is provided in (18). Probes mapping to the gene body are
not used. Using this gene-based methylation value, we then
compute moderated t-statistics using an empirical Bayes
framework (32). The same empirical Bayes procedure was
applied to gene expression data. Methylation differences
with false discovery rate (FDR) <0.05 and with absolute
difference in mean methylation beta levels between the two
groups of more than 0.1 were considered statistically signifi-
cant.Gene expression differenceswithFDR<0.05 andwith
a log2 fold change between two groups of more than 1 were
considered statistically significant. Using both t-statistics
for each gene, we then selected genes with opposite signs
of t-statistics, which indicates an anti-correlation between
DNAm andmRNAm expression, and further divided them
into two groups based on the directionality of differential
methylation: a hypermethylated group (HyperM) and a hy-
pomethylated (HypoM) group. Genes in each group were
ranked according to the integrative statistic, as described in
(18). Finally, we further filtered the gene lists using a mul-
tivariate regression framework of gene expression against
DNAmandCNV as covariates (and using both normal and
cancer samples), to select genes exhibiting a significant anti-
correlation between mRNA expression and DNAm. This
was done to ensure that (i) the anti-correlation between dif-
ferential mRNA expression and differential DNAm is due
to the same set of tumours, and (ii) to ensure that the anti-
correlation between DNAm and mRNA expression cannot
be explained by concomitant alterations at the CNV level.
Finding somatic copy number altered genes
After deriving the copy number call matrix, as described
above, we developed a procedure to identify those SCNA
that are associated with a corresponding change in gene ex-
pression. Gaussian distributions were fitted to the log2 ex-
pression values for each gene and for each cancer type, using
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maximum likelihood estimates of the mean and variance.
Based on this distribution, we can derive a simplified vector
for each gene, where samples with expression in the 5% left
tail were marked as underexpressed and samples with ex-
pression in the 5% right tail were marked as overexpressed.
Therefore, for each gene in each sample, we have informa-
tion as to whether it defines an amplification/deletion
and overexpression/underexpression event. From
this, we generate two binary matrices: one is an
Amplification/Overexpression call matrix where a matrix
entry is assigned 1 if it is both an amplification and an
overexpression event, and 0 otherwise. The other matrix is a
Deletion/Underexpression call matrix where a matrix entry
is assigned 1 if it is both a deletion and an underexpression
event, and 0 otherwise. For each call matrix, we select genes
that have at least one non-zero entry and then rank the
genes based on the number of non-zero entries in decreas-
ing order. The resulting two ordered gene lists correspond
to SCN gained and overexpressed genes (Amplification)
and SCN deleted and underexpressed genes (Deletion).
Finally, we further filtered the gene lists using a multivariate
regression framework of gene expression against DNAm
and CNV as covariates (and using both normal and cancer
samples), to select genes exhibiting a significant correlation
between mRNA expression and CNV. This was done to
ensure that (i) the correlation between differential mRNA
expression and SCNA is due to the same set of tumours,
and (ii) to ensure that the correlation between SCNA and
mRNA expression cannot be explained by concomitant
alterations at the DNAm level.
Finding significantly mutated genes
We use theMutSigCV software (35) to identify significantly
mutated genes which takes DNA replication time, expres-
sion and chromatin state into account when estimating the
background mutation rate.
Finding epigenetically regulated tissue-specific genes
We generated the epigenetically regulated tissue-specific
gene lists for each of 10 tissue types by comparing the
DNAm data as well as gene expression data of normal sam-
ples from one tissue type with that of other nine tissue types
using an empirical Bayes framework (32). Methylation dif-
ferences with FDR <0.05 and at least 30% of mean methy-
lation difference between two groups were considered sta-
tistically significant. Gene expression differences with FDR
<0.05 and log2 fold change between two groups more than
2 were considered statistically significant. Using both t-
statistics for each gene, we then selected genes with oppo-
site signs of t-statistics, which indicates an anti-correlation
between DNAm and mRNA, and further divided them
into two groups based on the directionality of differential
methylation: a hypermethylated group (HyperM) and a hy-
pomethylated group (HypoM). Genes in each group were
ranked according to the integrative statistic, as described in
(18). The significance of overlap between epigenetically reg-
ulated tissue-specific gene lists and epigenetically regulated
cancer altered gene lists for each cancer type was evaluated
using one tailed Fisher’s exact test.
Protein interaction network (PIN)
We used the 2015 March version from the Pathway Com-
mons (PC2) database (36) to build the PIN. In detail, this
was built by integrating the Human Protein Interaction
Database (HPRD), the National Cancer Institute Nature
Pathway Interaction Database (NCI-PID), the Interactome
(Interact) and the Biological General Repository for inter-
action Datasets (BioGRID). Protein interactions included
stable interactions like those defining protein complexes as
well as transient interactions like post-translational modi-
fications and enzymatic reactions found in signal transduc-
tion pathways. We focused on the largest connected compo-
nent of genes with Entrez ID identifiers, which amounted to
a connected network of 15 728 nodes and 1 910 396 inter-
actions. This PIN was further pruned by removing edges
which were not consistent with the signaling domain hier-
archy structure (see below for definition of signaling do-
mains). Thus, only edges with corresponding end nodes in
the following signaling domain combinations were allowed:
EC-EC, EC-MR, MR-IC and IC-IC, where EC = extra-
cellular, IC = intra-cellular, MR = membrane-receptor.
This resulted in a reduced PIN of 10 726 nodes and 1 306
162 interactions (maximally connected component). The
sparsity (i.e. the fraction of edges to total number of pos-
sible edges) of this PIN is 0.023.
Definition of signaling domains
Following (37), we annotated genes into five distinct
signaling domains: growth modulators (GM), secreted
factors (SF), membrane receptors (MR), intracellular
receptor substrates (ICRS) and intracellular non re-
ceptor substrates (ICNRS). These assignments were
made using main cellular localization data of the cor-
responding proteins, as given in the HPRD database.
Specifically, we first defined an intra-cellular domain
as all those GO-terms containing the following terms:
‘Nucleus’,‘Cytoplasm’,‘Ribosome’,‘Nucleolus’,‘Mitoc
hondri’,‘Endoplasmic reticulum’,‘Golgi’,‘Lysosome’,‘C
ytosol’,‘Cytoskeleton’,‘Nuclear’,‘Kinetochore’,‘Chrom
osome’,‘Endosome’,‘Intracellular’,‘Nucleoplasm’,‘Perin
uclear’,‘Centrosome’,‘Peroxisome’, ‘Microtubule’,‘Mic
rosome’,‘endosome’,‘Centriole’,‘Sarcoplasm’,‘Secretory
granule’,‘Endocytic vesicle’,‘cytoskeleton’,‘Peroxisom
al membrane’,‘Acrosome’,‘Zymogen granule’. For the
membrane-receptor (MR) domain we used: ‘Plasma
membrane’,‘Integral to membrane’,‘Cell surface’,‘Integral
to plasma membrane’,‘Cell projection’,‘Basolateral
membrane’,‘Axoneme’,‘Apical membrane’ and for the
extra-cellular (EC) domain:
‘Extracellular’,‘Cell junction’,‘Synapse’,‘Dendrite’,‘Sec
reted’,‘Synaptic vesicle’. The IC class was subdivided into
ICRS and ICNRS subclasses, according to whether the IC
annotated protein interacts with a MR (if yes, then ICRS)
or not (ICNRS). Similarly, the EC class was subdivided
further into GM and SF subclasses, according to whether
the EC annotated protein interacts with a MR (SF) or not
(GM).
Because genesmay be annotated tomultiple signaling do-
mains, for some analysis we used a coarse grained 2-domain
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assignment, whereby a gene annotated to both extracellu-
lar and transmembrane domains was allocated to ‘EC’, and
a gene annotated to both transmembrane and intracellular
domains was allocated as ‘IC’.
Comparison of shortest path distances among genes in the dif-
ferent alteration groups
To assess the inter-connectivity of the group of genes in
each alteration group in the PIN, we compared the distribu-
tion of the shortest path length between every pair of genes
within an alteration group and within each cancer type. We
selected the top 100 ranked genes with different alteration
types, including (i) Hypermethylated and underexpressed
genes (HyperM), (ii) Hypomethylated and overexpressed
genes (HypoM), (iii) SCN gained and overexpressed genes
(Amplification), (iv) SCNdeleted and underexpressed genes
(Deletion), (v) Mutated genes (Mutation). The shortest
paths length was estimated for each gene pair in the top-
ranked list, and the average shortest path lengths were com-
pared between different alteration groups within one can-
cer type. The comparison was done by computing the P-
values using one-tailed paired Wilcoxon rank-sum test be-
tween any two different alteration types and for each of
the 10 cancer types separately. For HyperM and other four
groups, we tested whether HyperM group has significantly
larger average shortest paths length than the other four
groups. For HypoM and other three groups (except Hy-
perM), we tested whether HypoM group has significantly
larger average shortest paths length than the other three al-
teration groups. ForMutation andAmplification/Deletion,
we tested whether Mutation group has significantly larger
average shortest paths length than Amplification/Deletion
groups. For Amplification and Deletion group, we tested
whether Amplification group has significantly larger aver-
age shortest paths length than Deletion group.
Comparison of signaling domain distribution within PIN
We did the enrichment analysis of signaling domains for
each alteration group by comparing the number of observed
genes in each domain with the number of expected genes
in each domain. This expected number is the number of
genes in an alteration group multiplied with the percent-
age of genes in each signaling domain. Here we combine
the extracellular and transmembrane domain as one big do-
main (EC+MR) (see subsection on signaling domain defi-
nitions), and use intracellular domain as the other domain.
The odds ratio (OR) and P-values were calculated using the
one-tailed Fisher’s exact test. These analyses were done in
two different ways: (i) using all the significant genes in each
alteration group, and (ii) selecting the same number of top-
ranked genes for each alteration group, which was chosen
as the minimum number for all five groups as determined in
(i).
Comparison of signaling domains distributions in specific
pathway
We downloaded signaling pathway information from
MSigDB (38). For each signaling pathway, we calculated
the number of genes undergoing functional DNAmor SCN
alterations and which mapped into either the extracellu-
lar (EC) or intracellular (IC) domain. A P-value was com-
puted using a one-tailed Fisher’s exact test to determine
whether genes with functional DNAm aberrations were en-
riched in the EC domain compared with SCNAs. A meta-
analysis P-value was computed by Fisher’s combined test
for each signaling pathway across 10 cancer types, and sig-
naling pathways with meta-analysis P-values below than
0.05 were deemed to exhibit a significant differential sig-
naling domain distribution between functional DNAm and
SCN alterations. To identify signaling pathways that exhibit
functional DNAm alterations preferentially in the extracel-
lular domain, we calculated the number of genes undergo-
ing functional DNAm alterations in the extracellular and
intracellular domains, respectively, and compared them to
the numbers of genes in these domains not exhibiting func-
tional DNAm alterations. P-value was computed using a
one-tailed Fisher’s exact test and a meta-analysis P-value
was computed by using Fisher’s combined test for each sig-
naling pathway across 10 cancer types.
RESULTS
Construction of putative DNAm and SCNA driven cancer
gene lists
We downloaded TCGA Illumina 450k DNAm, SCNA and
RNA-Seq gene expression data for a total of 10 cancer types
for which there were reasonable numbers of normal sam-
ples (‘Materials and Methods’ section, Supplementary Ta-
ble S1). We asked if functional DNAm alterations in cancer
are distinguishable from functional SCNAs in the context of
how they map onto a highly curated PPI network (‘Materi-
als and Methods’ section). This analysis was performed by
considering four separate classes of putative driver cancer
genes: (i) genes which exhibit a hypermethylated promoter
and underexpression in cancer, (ii) genes which exhibit a hy-
pomethylated promoter and overexpression in cancer, (iii)
genes with SCN loss and underexpression in cancer and
(iv) genes with SCN gain and overexpression in cancer.
The identification of these putative driver cancer gene sets
used state-of-the-art methods, which have previously been
used to successfully identify known driver genes at both
SCN and DNAm levels (‘Materials and Methods’ section)
(6,18,39). For instance, we applied the method used in the
breast cancer METABRIC study of Curtis et al. (39) to
identify SCN cancer drivers in the TCGA breast cancer set,
revealing a highly significant overlap of the TCGA-derived
driver list with the one derived from METABRIC (Sup-
plementary Figure S2). In the case of DNAm, we ignored
genes where the promoter DNAm change was not anti-
correlated to gene-expression change, since positive corre-
lations represent the minority of associations (18) and are
less likely to be linked causally (40). We note that this ap-
proach of focusing on anti-correlated patterns between pro-
moter DNAm and gene expression was used by us previ-
ously, successfully identifying a causal driver of endome-
trial cancer, the causal association of which was validated
experimentally (6,18). Besides imposing stringent levels of
statistical significance, we also demanded that differences in
DNAm andmRNA expression between normal and cancer
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be at least 10% and larger than 2-fold, respectively (Mate-
rials and Methods). Since DNAm and SCN variation can
simultaneously affect gene expression, our selection proce-
dure further filtered genes according to statistical signif-
icance in multivariate regression models with mRNA ex-
pression as the response variable and including DNAm and
SCNAas predictors (‘Materials andMethods’ section). The
resulting sets and numbers of genes for each of the 4 putative
cancer driver classes in each of the 10 TCGA cancer types
are listed in Supplementary Tables S2–5. The range in the
number of genes in each class across cancer types was (16
642), (94 368), (205 1877) and (161 1242) for HyperM, Hy-
poM, Amplification andDeletion respectively.We note that
for a given TCGA cancer type, the overlap between these 4
gene lists was minimal, especially between the DNAm and
SCNA groups (Supplementary Figure S3).
Functional DNA methylation alterations in cancer exhibit
lower interactome connectivity compared to corresponding
SCNAs and mutations
In order to objectively compare the topological properties
of these different putative cancer driver gene classes in a
PPI network, we need to select a given identical number
of top-ranked genes from each class. For a given TCGA
cancer type, we thus mapped the top-100 ranked genes
from each class onto our PPI network of 10 726 nodes
and 1 306 162 edges (‘Materials and Methods’ section).
For each set of top ranked genes, we studied the distribu-
tion of their connectivities/degrees (i.e. the number of near-
est neighbors of each gene in the list) in the network. In
each of the 10 cancer-types we observed a highly statistically
significant difference (Wilcoxon rank sum test P < 1e-5),
with genes undergoing differential methylation and differ-
ential expression exhibiting a significantly lower connectiv-
ity compared to genes undergoing simultaneous SCN and
gene expression alterations (Figure 1; Supplementary Fig-
ures S4 and 5). We also observed statistically significant dif-
ferences between the hypermethylated/underexpressed gene
class and the hypomethylated/overexpressed class in five
cancer types, with the former exhibiting lower connectivity
(Table 1).
Next, we obtained the distribution of the shortest path
length between all gene-pairs within one of the four classes
and asked if their distributions differed. This assesses how
close the corresponding genes in each set are to each other
in the network. We also included the top 100 ranked genes
based on mutational frequency (‘Materials and Methods’
section, Supplementary Table S6). This analysis showed
that, across all 10 cancer-types, genes undergoing differen-
tial methylation and differential expression generally exhib-
ited longer shortest path lengths, compared to genes under-
going simultaneous SCN and gene expression alterations,
or to frequently mutated genes (Supplementary Figure S6
and Supplementary Table S7). We note that the longer
shortest path lengths exhibited by genes undergoing differ-
ential methylation and differential expression is consistent
with their lower node-connectivity.
Functional epigenetic and genetic cancer alterations map
preferentially into different signaling pathway domains
Important properties such as gene expression variance are
known to vary according to the gene’s signaling domain
(37). Following Komurov (37), we henceforth categorized
all genes of our PPI network into five signalling hierar-
chy classes: (i) growth modulators (GM), (ii) secreted fac-
tors (SF), (iii) membrane receptors (MR), (iv) intracellu-
lar receptor substrates (ICRS) and (v) intracellular non-
receptor substrates (ICNRS) (‘Materials andMethods’ sec-
tion). We validated our signaling domain associations with
an independent gene-family annotation from the Molecu-
lar Signatures Database (MSigDB) (38), which showed that
GMs and SFs were mostly growth factors and cytokines,
MRs were mostly cell surface differentiation markers and
receptor tyrosine kinases, ICRS were mostly kinases, whilst
transcription factors dominated the ICNRS class (Supple-
mentary Figure S7). Each of the five previously consid-
ered gene classes (Supplementary Tables S2–6) were then
mapped onto these signaling domains. Combining GM and
SF into an extra-cellular (EC) domain class, as well as ICRS
and ICNRS into an intra-cellular (IC) category, and fur-
ther combining the EC class with the transmembrane (MR)
class, we observed a striking difference between the pat-
terns of enrichment of the various driver alterations in rela-
tion to whether they mapped to the IC or EC+MR classes
(Figure 2). Specifically, in 9/10 cancer types, we observed
that genes undergoing hypermethylation and underexpres-
sion were significantly (Fisher-test P < 0.05) more likely to
map to the EC+MR signaling domain compared to the IC
domain (Figure 2A). This pattern was generally stronger for
hypomethylated and overexpressed genes with 10/10 can-
cer types exhibiting significance at P < 0.05 level (Figure
2B). In contrast, SCNAs revealed an exact opposite pattern,
with deleted underexpressed genes mapping more likely to
the IC domain in 9/10 cancer types (Figure 2C) and with
amplified overexpressed genes doing so also in 9/10 can-
cer types (Figure 2D). Genetic mutations did not reveal
a consistent pattern of differential enrichment among sig-
naling domains (Figure 2E). Meta-analysis P-values con-
firmed that all of these associations were highly significant
across cancer-types (Supplementary Table S8). To ensure
that these results were not biased by different numbers of
genes in each molecular alteration group, we repeated the
analysis setting the number of genes in each group to be
the same (the smallest number among all five gene groups),
confirming that results are robust (Supplementary Figure
S8 and Supplementary Table S9).
Although the previous results were obtained on sets of
genes that exhibit differences between normal and cancer
tissue, we asked if the enrichment of epigenetically altered
genes within the EC+MR class is also true for epigeneti-
cally regulated tissue-specific genes in a given normal tissue-
type. To assess this, we derived for each tissue-type a set
of genes which were hypermethylated and underexpressed,
or hypomethylated and overexpressed, in that tissue com-
pared to the other nine tissue types considered here (‘Mate-
rials and Methods’ section). We observed that these tissue-
specific DNAm and mRNA expression altered genes ex-
hibited significant overlap with the previously derived can-
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Figure 1. Functional epigenetic alterations exhibit lower interactome connectivity than their SCNA counterparts. Left panels: for two cancer types (COAD
and HNSC), the PPI network is depicted (interactions have been suppressed) with nodes (genes/proteins) colored according to the type of functional al-
teration and with the radial distance from the center indicating their connectivity (nodes in the center have higher connectivity and connectivity decreases
radially outward). We defined for each cancer type four types of functional alterations at the gene-level, including the 100 top-ranked (i) hypermethylated
and underexpressed genes (HyperM), (ii) hypomethylated and overexpressed genes (HypoM), (iii) gain of copy-number and overexpressed genes (Amplifi-
cation) and (iv) CN deleted and underexpressed genes (Deletion). Classes (i)+(ii) are shown here as one group (DNAm) indicated by color magenta, while
classes (iii)+(iv) represent another group (CNV) indicated by color cyan. Right panels: Boxplots of the connectivity (degree) for the same two groups of
genes. The P-value is from aWilcoxon rank sum-test comparing the connectivity of genes exhibiting simultaneous differential methylation and differential
expression (i.e. classes (i)+(ii)) versus the connectivity of genes exhibiting simultaneous CNV and differential expression (classes (iii)+(iv)). Analogous
plots for all other cancer-types are shown in Supplemental Figure S4.
cer altered genes (Supplementary Figure S9) and that these
tissue-specific genes were therefore also enriched among
the EC+MR signaling domain class (Supplementary Fig-
ure S10 and Supplementary Table S10). This data is con-
sistent with the view that tissue-specific genes are often dif-
ferentially expressed in cancer and that this deregulation is
associated with epigenetic alterations (41).
Pan-cancer wide analysis identifies signaling pathways ex-
hibiting differential signaling domain enrichment of epige-
netic versus genetic alterations
In order to identify specific signaling pathways which ex-
hibit differential signaling domain enrichment between
DNAm and SCNAs, we computed the number of genes
undergoing functional DNAm or SCN alterations in each
major signaling pathway domain and for all major signal-
ing pathways (‘Materials and Methods’ section). For each
cancer-type and signaling pathway we obtained a P-value
to test for enrichment of functional DNAm alterations in
the extracellular domain. In a meta-analysis over all 10
cancer types, specific signaling pathways emerged as ex-
hibiting a consistent differential enrichment pattern across
cancer-types (Table 2). Among themost highly ranked path-
ways, we found G-Protein Coupled Receptor (GPCR) sig-
naling, immune system and chemokine signaling and JAK-
STAT signaling (Table 2).WNT-signaling, a hotspot of age-
associated differential DNAm in normal tissue (17), was
also one of the highest ranked pathways, attaining signifi-
cant P-values in 7/10 tumor types (Combined Fisher-test
P < 0.0001) (Table 2). Focusing on the canonical WNT-
signaling pathway, we confirmed a clear differential enrich-
ment across signaling domains, with most of the epigenetic
alterations occurring in the extra-cellular domain (Fig-
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Figure 2. Functional epigenetic alterations preferentially target genes in the extra-cellular/transmembrane domains, with SCNA counterparts preferen-
tially mapping to the intra-cellular domain. Top Row: Barplots comparing the observed and expected numbers of genes for two different signaling domains
(extracellular+transmembrane receptor: EC+MR, and intra-cellular: IC) forHyperM group (hypermethylated and underexpressed genes) across 10 TCGA
cancer types. P-values are from a one-tailed Fisher’s exact test. Alternative hypothesis is that the odds ratio of finding more genes mapping to the EC+MR
domain is >1. Row-2: As before but for the HypoM group (hypomethylated and overexpressed genes). P-values are from a one-tailed Fisher’s exact test.
Alternative hypothesis is that the odds ratio of finding more genes mapping to the EC+MR domain is >1. Middle Row: As before but for the Deletion
group (SCN deletion and underexpressed genes). P-values are from a one-tailed Fisher’s exact test. Alternative hypothesis is that the odds ratio of finding
more genes mapping to the EC+MR domain is <1. Second last row: As before but for Amplification group (SCN gain and overexpressed genes). P-values
are from a one-tailed Fisher’s exact test. Alternative hypothesis is that the odds ratio of finding more genes mapping to the EC+MR domain is <1. Last
row: As before, but for Mutation group (mutated genes). P-values are from a one-tailed Fisher’s exact test. Alternative hypothesis is that the odds ratio of
finding more genes mapping to the EC+MR domain is >1.
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Table 1. Putative functional epigenetic drivers exhibit lower connectivity than their functional SCN counterparts
P-values of one-tailed Wilcoxon test comparing connectivity
COAD HyperM HypoM Amplification Deletion
HyperM NA 0.95 1 1
HypoM 0.05 NA 1 1
Amplification 6e-13 5e-07 NA 0.921
Deletion 1e-14 1e-08 0.079 NA
HNSC HyperM HypoM Amplification Deletion
HyperM NA 0.991 1 1
HypoM 0.009 NA 1 1
Amplification 7e-14 1e-09 NA 0.578
Deletion 3e-15 2e-11 0.423 NA
BLCA HyperM HypoM Amplification Deletion
HyperM NA 0.97 1 1
HypoM 0.03 NA 1 1
Amplification 4e-12 2e-07 NA 0.153
Deletion 4e-08 1e-04 0.848 NA
BRCA HyperM HypoM Amplification Deletion
HyperM NA 0.729 1 1
HypoM 0.272 NA 1 1
Amplification 1e-10 4e-09 NA 0.034
Deletion 2e-05 2e-04 0.966 NA
KIRC HyperM HypoM Amplification Deletion
HyperM NA 0.734 1 1
HypoM 0.266 NA 1 1
Amplification 6e-06 4e-05 NA 0.999
Deletion 6e-14 1e-12 9e-04 NA
LIHC HyperM HypoM Amplification Deletion
HyperM NA 0.65 1 1
HypoM 0.351 NA 1 1
Amplification 4e-13 3e-09 NA 0.51
Deletion 1e-10 8e-08 0.491 NA
LUSC HyperM HypoM Amplification Deletion
HyperM NA 1 1 1
HypoM 3e-04 NA 1 0.991
Amplification 2e-12 1e-04 NA 0.035
Deletion 5e-10 0.009 0.965 NA
LUAD HyperM HypoM Amplification Deletion
HyperM NA 0.247 1 1
HypoM 0.754 NA 1 1
Amplification 8e-14 2e-13 NA 0.294
Deletion 3e-10 2e-10 0.707 NA
THCA HyperM HypoM Amplification Deletion
HyperM NA 0.254 0.849 0.938
HypoM 0.757 NA 1 1
Amplification 0.155 3e-04 NA 0.98
Deletion 0.064 1e-06 0.02 NA
UCEC HyperM HypoM Amplification Deletion
HyperM NA 0.998 1 1
HypoM 0.002 NA 1 1
Amplification 6e-12 6e-06 NA 0.611
Deletion 4e-14 5e-07 0.39 NA
Table lists one-tailed Wilcoxon rank sum test P-values comparing the connectivity (degree) distribution of the top ranked 100 genes in each molecular
alteration group between each other, and for each of 10 TCGA cancer types. For each cancer type, the alternative hypothesis being tested is that the
connectivity of the gene-class in the column is smaller than that of the gene class indicated in the row.
ure 3A). Aggregating numbers of alterations across all 10
cancer-types further confirmed a strong differential enrich-
ment within the WNT-signalling pathway, the Chemokine
signaling pathway and the JAK-STAT signaling pathway
(Figure 3B). We note that many of the identified signal-
ing pathways, including WNT-signaling, exhibited an en-
richment toward functional DNAm alterations in the extra-
cellular domain regardless of the genomic pattern of alter-
ation (Supplementary Table S11). Importantly, we did not
observe any signaling pathway to be significant if we tested
for a reverse enrichment pattern, i.e. one with more func-
tional DNAm alterations in the intra-cellular domain, ei-
ther in comparison to genes undergoing functional SCNAs
or not (data not shown), further supporting the view that
cancer cells exhibit a preference for extracellular and trans-
membrane genes to undergo epigenetic deregulation.
Besides WNT-signaling, chemokine signaling is also
thought to play a major role in cancer progression, by
upsetting the balance between a favorable Th1-type and
an adverse Th2-type immune response (42–44). Mapping
the functional alterations across cancer-types onto a global
chemokine signaling pathway confirmed a striking differ-
ential enrichment, with functional epigenetic deregulation
happening mostly in the extracellular domain (Figure 4A).
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Figure 3. Differential signaling domain enrichment of epigenetic versus genetic alterations within the canonical WNT-signaling pathway. (A) Map of the
canonical WNT-signaling pathway, with genes undergoing different types of alterations (indicated in different colors) across 10 cancer types. DNAm:
a gene exhibits only functional epigenetic aberrations, whether it is hypermethylated or hypomethylated, in one or more cancer types. SCNA: a gene
exhibits only SCN aberrations, whether it is amplified or deleted, in one or more cancer types. DNAm/SCNA: a gene exhibits both functional epigenetic
aberrations and SCN aberrations in different cancer types. Mutation: a gene exhibits only mutations in one ore more cancer types. From left to right is the
direction of cells from outside to inside. (B) Barplots comparing the cumulative sum of the alterations over all 10 cancer types in three signaling pathways,
distributed according to different signaling domains (IC-intracellular and EC-extracellular) and alteration type (DNAm: functional epigenetic aberrations
and SCNA: SCN aberrations). From left to right are canonical WNT signaling pathway as indicated in panel A, Chemokine signaling pathway and JAK-
STAT signaling pathway. P-values were calculated using a one-tailed Fisher’s exact test, testing the alternative hypothesis that there are proportionally
more epigenetic alterations in the EC domain compared to SCNAs.
Table 2. Top-ranked signaling pathways exhibiting a significant differential signaling domain distribution between functional DNAmethylation and SCN
alterations based on a meta-analysis over 10 cancer types
Signaling pathway BLCA BRCA COAD HNSC KIRC LIHC LUAD LUSC THCA UCEC ALL
GPCR 0.103 0.024 0.116 4e-05 2e-04 0.022 0.031 0.002 1 0.116 7e-10
IMMUNE SYSTEM 0.006 1 0.017 0.117 0.001 0.118 8e-04 0.176 0.009 0.016 2e-08
WNT 0.061 0.016 0.006 0.015 0.008 0.011 0.008 0.035 0.1 1 8e-08
CHEMOKINE 0.05 0.005 0.611 0.001 9e-04 0.053 0.5 0.133 0.05 0.455 2e-06
HEMOSTASIS 0.045 4e-05 0.551 0.004 0.072 0.154 0.038 0.498 1 0.022 2e-06
FOCAL ADHESION 0.331 0.038 0.261 0.056 0.095 0.182 0.083 0.005 1 0.006 1e-04
JAK STAT 0.133 0.011 0.035 0.119 0.017 0.111 0.22 0.192 0.1 1 5e-04
TOLL LIKE RECEPTOR 1 0.059 1 0.048 0.005 0.083 0.045 0.091 1 0.029 0.001
LIPID METABOLISM 0.03 0.013 0.082 0.154 1 0.2 0.015 1 0.044 1 0.003
DIABETES 0.1 0.004 0.429 0.1 1 0.012 0.077 0.6 1 1 0.012
PDGF 1 0.032 0.029 0.045 1 0.091 0.308 0.333 1 0.031 0.014
P-values for each cancer type were calculated using a one-tailed Fisher’s exact test. A meta-analysis P-value was calculated for each signaling pathway
using Fisher’s combined test.
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Figure 4. Differential signaling domain enrichment of epigenetic versus genetic alterations within the chemokine signaling pathway. (A) As Figure 3A, but
now for the chemokine signaling pathway. (B) Heatmap depicts pattern of epigenetic deregulation in cancer for chemokine and chemokine receptors across
10 cancer types. HyperM(F): gene exhibits simultaneous hypermethylation and underexpression in cancer. HyperM(NF): gene is hypermethylated but not
underexpressed. HypoM(F): gene exhibits significant hypomethylation and overexpression. HypoM(NF): gene is hypomethylated but not overexpressed.
NC: gene shows no significantDNAmchange in cancer. (C)Heatmaps depict Pearson correlation coefficients (PCCs) of gene expression for each chemokine
and chemokine receptor with DNMT1 or EZH2, as computed using only tumor samples from each tumor type. Gene symbols are marked in different
colors, indicating significant and directionally consistent correlation patterns across different cancer types. Gray: a gene shows no significantly consistent
correlation pattern. Orange: a gene shows significantly consistent positive correlation with DNMT1 or EZH2. Blue: a gene shows significantly consistent
negative correlation with DNMT1 or EZH2.
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We verified for individual chemokines and chemokine re-
ceptors, that patterns of epigenetic deregulation were highly
consistent between cancer types (Figure 4B, Empirical P <
0.001), demonstrating that these patterns of deregulation
transcend the tissue/cancer type.
Two important epigenetic enzymes which are universally
overexpressed in cancer (45), and which are known to influ-
enceDNAm levels areDNMT1 andEZH2 (46). Given their
role in suppressing specific Th1-type chemokines in ovar-
ian cancer (47), we asked if DNAm patterns of epigenet-
ically deregulated genes in the chemokine signaling path-
way were significantly correlated (or anti-correlated) with
expression of either DNMT1 or EZH2, and how this varied
across cancer-types. Interestingly, this revealed that some
chemokines and chemokine receptors were generally always
either correlated or anti-correlated with expression of these
two enzymes across cancer-types (Figure 4C), pointing to-
ward universal patterns of co-expression with key epige-
netic enzymes. Interestingly, chemokines or chemokine re-
ceptors exhibiting consistent hypermethylation and under-
expression in cancer, exhibited expression patterns across
tumors that were more likely to be consistently negatively
correlated with expression of EZH2 or DNMT1 (or both)
(Figure 4B and C). In contrast, for those exhibiting con-
sistent hypomethylation/overexpression in cancer, their ex-
pression across tumors is more likely to be consistently pos-
itively correlated with EZH2 orDNMT1 (or both).We note
that for many genes that showed a significant and consistent
correlation with expression of EZH2/DNMT1, about half
of these (e.g. CCL14, CCL15, CXCL9, CXCL10, CXCL11,
CXCR3, CXCR6) did not have any 450k probe mapping to
their TSS200, first exon or TSS1500 regions, not allowing
DNAm changes around the promoter to be assessed.
DISCUSSION
Here we have conducted a systems-level comparative anal-
ysis of functional DNAm and SCN alterations, including
mutations, in cancer. Our three key findings, (i) that func-
tional DNAm alterations exhibit a significantly lower con-
nectivity compared to functional SCNAs andmutations, (ii)
that functional DNAm alterations tend to target genes in
the extracellular and transmembrane domains and (iii) that
there exist specific signaling pathways (e.g. chemokine and
WNT signaling) which exhibit such preferential epigenetic
deregulation in the extracellular domain independently of
cancer-type, shed novel insight into the potentially distinc-
tive role of these alteration types in cancer.
Previous studies have shown that DNAm changes in can-
cer and aging are enriched for bivalently and PRC2 marked
genes, which in turn are highly enriched for developmental
transcription factors (TFs) (48–52). These TFs occupy pe-
ripheral positions in a PPI network like the one considered
here, which does not include explicit regulatory protein–
DNA interactions. However, that TFs map to the periphery
of our PPI network, does not imply that functional DNAm
alterations in cancer would also occupy peripheral posi-
tions, because most of the PRC2 marked TFs undergoing
promoter DNAm in cancer are not altered at the expression
level (as they are generally not expressed in the normal tis-
sue to begin with) (53). Thus, it is not a foregone conclusion
that the subset of genes undergoing epigenetic deregulation
in cancer would necessarily mark nodes of low connectiv-
ity. Indeed, our second key finding indicates that the lower
connectivity of functional DNAm alterations in cancer, is
driven mainly by genes encoding growth modulators and
secreted factors.
Interestingly, a similar enrichment for genes in the extra-
cellular domain, was also observed for tissue-specific genes
for which their tissue-specific expression level is strongly as-
sociated with the degree of DNAm at their promoter. We
observed that this similar enrichment can be explained by
the fact that there was considerable overlap between the epi-
genetically regulated tissue-specific genes and those genes
undergoing simultaneous differential methylation and ex-
pression in cancer, consistent with previous findings (41).
Indeed, one of the main cancer hallmarks is a lack of differ-
entiation, so it should not be surprising that tissue-specific
genes are preferentially altered in cancer. Hence, our obser-
vation that functional DNAm alterations in cancer are en-
riched within the extracellular domain can be partially ex-
plained by the corresponding enrichment of tissue-specific
genes.
The enrichment of functional DNAm alterations within
the extracellular domain, in contrast to SCNAs (which were
over-represented in the intracellular space) and to genetic
mutations (which did not exhibit any differential enrich-
ment pattern), was highly consistent across cancer-types, at-
testing to its biological significance. Our third key finding
showed that there exist specific signaling pathways which
are more prone to epigenetic deregulation in their extracel-
lular signaling domain, irrespective of cancer-type. This in-
cluded two signaling pathways of critical importance in car-
cinogenesis: WNT- and chemokine signaling (44,54).
We stress that our observation that these specific path-
ways are prone to epigenetic deregulation irrespective of
cancer-type, is, to the best of our knowledge, an en-
tirely novel insight. It is important, because evidence is
mounting that epigenetic alterations, or genetic modula-
tion of epigenetic regulators, also contribute to carcinogen-
esis (1,6,55,56). Like genetic mutations and somatic copy-
number changes, epigenetic alterations also accrue in nor-
mal cells as a function of age and as a function of expo-
sure to cancer risk factors. However, because the epigenome
is more easily modulated than the genome, the epigenome
is the prime candidate to mediate the effects of environ-
mental exposures (57). These exposures are, by definition,
cell-extrinsic, mediated by alterations in the environmen-
tal niche, in which adult stem-cells of the underlying tissue
reside. It is therefore plausible that cellular adaptation to
extra-cellular stresses would involve a mechanism that tar-
gets the proteins that mediate the extra-cellular signals. Al-
though signal transduction is a complex biological process,
involving proteins at every layer of the signaling domain
hierarchy, it can be argued that the most direct means to
adapt to specific extra-cellular signals is through modula-
tion of extracellular factors and to a less degree by trans-
membrane receptors. Indeed, it has already been demon-
strated that expression variability, as assessed across a large
number of different normal tissue types, is maximal for
genes whose main cellular localization at the protein level
is in the extra-cellular domain (37). Many expression mark-
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ers of specific cell-types also map to the cell-surface. As we
have shown here, the subset of genes in the extracellular and
transmembrane domains which get functionally altered in
cancer, appear to do so preferentially through alterations in
DNAm. Thus, epigenetic deregulation of extracellular sig-
naling domain genes in cancer may reflect adaptation of
cancer cells to a selection process driven by specific environ-
mental stresses. This interpretation is strongly supported
in the case of the WNT-signaling pathway, as many previ-
ous studies have demonstrated thatWNT activity in epithe-
lial stem-cells is controlled by cell-extrinsic factors and that
modulation of WNT activity affects sensitivity of cells to
DNA damage, thus linking epigenetic deregulation which
may happen early in carcinogenesis to an increased predis-
position to acquire genetic alterations (58–61).
The role of the immune response in controlling the risk
of distant metastasis and hence of clinical outcome in can-
cer is well established (62,63). A long-standing observa-
tion, supported by analysis of gene expression data, is
that a T-helper-1 type immune response is generally asso-
ciated with a favorable prognosis, in contrast to an oppos-
ing macrophage polarization program which promotes an
unfavorable T-helper-2 type response (42,43). The impor-
tant role of epigenetics in shaping the type of immune re-
sponse in the tumormicroenvironment was recently demon-
strated by Peng et al. (47), where it was shown how epige-
netic mediated silencing of specific Th1-type chemokines
could promote ovarian cancer progression and lessen the
therapeutic efficacy of programmed death-ligand 1 check-
point blockade. Unfortunately, the specific chemokine lig-
ands considered by Peng et al. (e.g. CXCL9 and CXCL10)
do not have 450k probes mapping to their promoters and
our study also excluded ovarian cancer due to the lack of
an appropriate normal reference. Nevertheless, our pan-
cancer wide analysis of the chemokine signaling pathway
revealed a striking pattern of epigenetic deregulation, with
several chemokines/chemokine receptors exhibiting consis-
tent hypermethylation and underexpression in cancer, also
exhibiting expression patterns (across tumors) that corre-
lated negatively with either DNMT1 or EZH2 (or both). It
is very likely that these chemokine genes play a tumor sup-
pressor role in cancer, and their consistent negative correla-
tion with expression of epigenetic enzymes such asDNMT1
or EZH2, suggest that their underexpression may be un-
der epigenetic control. For instance, our analysis identified
promoter hypermethylation and underexpression of ligand
CXCL12 in six cancer types, and previous studies have re-
ported epigenetically induced silencing of this gene in breast
cancer (64), colon cancer (65) and non-small cell lung can-
cers (66). Hypermethylation of CXCL12 in non-small cell
lung cancer has also been reported to be a poor prognos-
tic marker (66). Another interesting chemokine ligand is
CXCL14, which we observed to be hypermethylated and
underexpressed in two cancer types (breast and colon), but
which exhibited a distinctive anti-correlative expression pat-
tern with EZH2/DNMT1 in most cancer types. Supporting
this, epigenetic silencing of CXCL14 has been found to pro-
mote progression of breast (67), colorectal (68) as well as
gastric cancer (69).
In stark contrast to DNAm, functional SCNAs appear
to preferentially target genes in the intra-cellular domain,
affecting central processes such as the cell-cycle. Kinases,
phosphatases and other intra-cellular receptor substrates
are characterized by a significantly higher level of sig-
naling promiscuity and centrality. Disruption of genes in
this signaling domain may contribute to increased cell-
proliferation, but largely also toward an increased cellular
resistance and robustness (70,71).
In summary, this work exposes a deep subtle difference
between functional epigenetic and genetic alterations in
cancer, suggesting that thesemolecular alterationsmay con-
tribute in distinct ways to the carcinogenic process.
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